Abstract
Cyclic nucleotide phosphodiesterase (PDE), that is a multigenic enzyme superfamily ubiquitously distributed in mammalians, mainly contributes to intracellular signaling regulation. Its various isozymes specifically control in a spatio-temporal manner intracellular levels of cAMP and cGMP downstream receptor activation and nearby functional proteins. The PDE superfamily is constituted by 11 gene families (PDE1-PDE11), comprising 21 genes represented by more than 100 mRNA products due to alternative splicing. Among them, PDE3, PDE4 and PDE5 were viewed as therapeutic targets and therefore, due to the successful development of Viagra™ (sildenafil, potent selective PDE5 inhibitor), the knowledge in PDE field burst out with the help of academic/pharmaceutical collaborations. Organic medicinal chemistry, using crystallographic and docking approaches, has focused its search on the catalytic pocket of PDEs, leaving aside the development of variant subtype specific PDE inhibitors and activators. This review firstly describes the various properties of each PDE isozyme, focusing particularly on their regulatory domains, mainly located in the N-terminus. Thereafter, we review the possible peptidic regulations of PDE activity itself, then the PDE anchoring in macromolecular complexes and finally the direct interaction of PDE with some critical intracellular proteins, such as β-arrestin, immunophilin and proteins containing SH3-domain. Altogether, it appears that a peptidic approach would be helpful to study the intrinsic PDE regulation of each subfamily, and thereafter the PDE peptidic motifs implicated as well as PDE location in signaling cascades. Taking in account the various regulatory PDE domains could lead to design new peptides to conceive variant specific inhibitors as well as activators in a therapeutical goal.
Keywords: PDEs, regulatory domain, cAMP /cGMP signaling, peptide motif, protein/protein interaction
Current Pharmaceutical Design
Title: Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Volume: 16 Issue: 9
Author(s): Therese Keravis and Claire Lugnier
Affiliation:
Keywords: PDEs, regulatory domain, cAMP /cGMP signaling, peptide motif, protein/protein interaction
Abstract: Cyclic nucleotide phosphodiesterase (PDE), that is a multigenic enzyme superfamily ubiquitously distributed in mammalians, mainly contributes to intracellular signaling regulation. Its various isozymes specifically control in a spatio-temporal manner intracellular levels of cAMP and cGMP downstream receptor activation and nearby functional proteins. The PDE superfamily is constituted by 11 gene families (PDE1-PDE11), comprising 21 genes represented by more than 100 mRNA products due to alternative splicing. Among them, PDE3, PDE4 and PDE5 were viewed as therapeutic targets and therefore, due to the successful development of Viagra™ (sildenafil, potent selective PDE5 inhibitor), the knowledge in PDE field burst out with the help of academic/pharmaceutical collaborations. Organic medicinal chemistry, using crystallographic and docking approaches, has focused its search on the catalytic pocket of PDEs, leaving aside the development of variant subtype specific PDE inhibitors and activators. This review firstly describes the various properties of each PDE isozyme, focusing particularly on their regulatory domains, mainly located in the N-terminus. Thereafter, we review the possible peptidic regulations of PDE activity itself, then the PDE anchoring in macromolecular complexes and finally the direct interaction of PDE with some critical intracellular proteins, such as β-arrestin, immunophilin and proteins containing SH3-domain. Altogether, it appears that a peptidic approach would be helpful to study the intrinsic PDE regulation of each subfamily, and thereafter the PDE peptidic motifs implicated as well as PDE location in signaling cascades. Taking in account the various regulatory PDE domains could lead to design new peptides to conceive variant specific inhibitors as well as activators in a therapeutical goal.
Export Options
About this article
Cite this article as:
Keravis Therese and Lugnier Claire, Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs, Current Pharmaceutical Design 2010; 16 (9) . https://dx.doi.org/10.2174/138161210790963760
DOI https://dx.doi.org/10.2174/138161210790963760 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Function of Cytosolic Chaperones in Tom70-Mediated Mitochondrial Import
Protein & Peptide Letters Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Home Oxygen Therapy for the 21st Century
Current Respiratory Medicine Reviews Alzheimers and Dementia in the Oldest-Old: A Century of Challenges
Current Alzheimer Research Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Meet Our Editor:
Current Hypertension Reviews Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry